<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Lab Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Lab Med</journal-id>
      <journal-id journal-id-type="publisher-id">ALM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Laboratory Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2234-3806</issn>
      <issn pub-type="epub">2234-3814</issn>
      <publisher>
        <publisher-name>The Korean Society for Laboratory Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25729732</article-id>
      <article-id pub-id-type="pmc">4330180</article-id>
      <article-id pub-id-type="doi">10.3343/alm.2015.35.2.257</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
          <subj-group subj-group-type="heading">
            <subject>Diagnostic Hematology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>BRAF</italic> V600E and <italic>MAP2K1</italic> Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma Cases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Shin</surname>
            <given-names>Sang-Yong</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lee</surname>
            <given-names>Seung-Tae</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Hee-Jin</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ki</surname>
            <given-names>Chang-Seok</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jung</surname>
            <given-names>Chul Won</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Jong-Won</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kim</surname>
            <given-names>Sun-Hee</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Laboratory Medicine &amp; Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Sun-Hee Kim. Department of Laboratory Medicine &amp; Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-2704, Fax: +82-2-3410-2719, <email>sunnyhk@skku.edu</email></corresp>
        <corresp>Co-corresponding author: Seung-Tae Lee. Department of Laboratory Medicine &amp; Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-0290, Fax: +82-2-3410-2719, <email>nb.seungtae.lee@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>2</month>
        <year>2015</year>
      </pub-date>
      <volume>35</volume>
      <issue>2</issue>
      <fpage>257</fpage>
      <lpage>259</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>22</day>
          <month>8</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Korean Society for Laboratory Medicine.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>Differentiation of classic hairy cell leukemia (HCL-c) from HCL-variant (HCL-v) or splenic marginal zone lymphoma (SMZL) is important owing to their different treatment strategies and prognostic implications. Recently, testing for <italic>BRAF</italic> V600E mutations was suggested as an important diagnostic option for HCL-considering that it was exclusively detected in almost all cases [<xref rid="B1" ref-type="bibr">1</xref>]. The <italic>BRAF</italic> V600E mutation has been reported to be absent in most cases of immunoglobulin variable heavy chain rearrangements 4-34 (IGHV4-34)-positive HCL-c, HCL-v, and SMZL [<xref rid="B2" ref-type="bibr">2</xref>]. However, it was recently reported that high prevalence of <italic>MAP2K1</italic> mutation is observed in IGHV-34-positive HCL-c (5/7, 71.4%) [<xref rid="B3" ref-type="bibr">3</xref>].</p>
    <p>We investigated the presence of <italic>BRAF</italic> V600E and <italic>MAP2K1</italic> mutations in four HCL-c, two HCL-v, and four SMZL cases involving the bone marrow that were diagnosed between June 2005 and June 2014 at our hospital. HCL and SMZL was diagnosed in accordance with the 2008 WHO classification of tumors of hematopoietic and lymphoid tissues [<xref rid="B4" ref-type="bibr">4</xref>]. HCL-c was defined as the expression of Annexin A1, CD20, CD22, CD11c, CD103, and CD25. HCL-v was defined as the negative expression of CD25 and Annexin A1 [<xref rid="B4" ref-type="bibr">4</xref>]. Real-time PCR was performed by using the Real Q <italic>BRAF</italic> V600E Detection Kits (BioSewoom Inc., Seoul, Korea) on the 7500 Fast Real-Time System (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions [<xref rid="B5" ref-type="bibr">5</xref>]. Mutant enrichment 3'-modified oligonucleotide (MEMO)-PCR and sequencing analysis for the <italic>BRAF</italic> V600E mutation were performed as previously described [<xref rid="B6" ref-type="bibr">6</xref>]. We designed the sequencing primers for <italic>MAP2K</italic>: exon 2 (forward) 5'-TTCTCTGGTGACAGTATTGACTTG-3', (reverse) 5'-CCCTGAGAAATAATCCAATTACC-' and exon 3 (forward) 5'-CATCCCTTCCTCCCTCTTTC-3', (reverse) 5'-CTCTTAAGGCCATTGCTCCA-3'. Sequencing was performed by using the Big-Dye Terminator Cycle Sequencing Ready Reaction Kit on the ABI Prism 3130 Genetic Analyzer (Applied Biosystems). The DNA extracted from bone marrow aspirate slide was used for sequencing analysis.</p>
    <p>We detected the <italic>BRAF</italic> V600E mutation in all HCL-c cases either by real-time PCR or by the MEMO-sequencing method (<xref ref-type="table" rid="T1">Table 1</xref>). All SMZL and HCL-v cases were negative for <italic>BRAF</italic> V600E on both real-time PCR and MEMO-sequencing analyses. The <italic>MAP2K1</italic> mutation analysis of three HCL-c cases, one HCL-v case, and three SMZL cases revealed negative results.</p>
    <p>The most common types of <italic>BRAF</italic> mutation involve exon 15, and the substitution from valine to glutamate at the 600th amino acid (V600E) constitutes &gt;90% of all reported cases of mutation. <italic>BRAF</italic> mutations in hematological malignancy are relatively rare [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>]. In 2011, Tiacci et al. [<xref rid="B1" ref-type="bibr">1</xref>] reported that nearly all cases of HCL-c harbored the <italic>BRAF</italic> V600E mutation, although this mutation was not detected in any other B cell lymphomas including SMZL; this finding is in agreement with that of other studies [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. Presently, <italic>BRAF</italic> V600E mutation analysis is considered to be the most useful diagnostic tool for differentiating HCL from related lymphomas. We also confirmed the presence of <italic>BRAF</italic> V600E in all HCL-c cases, but not in HCL-v or SMZL cases.</p>
    <p>Recently, <italic>MAP2K1</italic> mutation was identified in a subset of HCL patients: 6/15 of IGHV-34-negative HCL-v, 4/9 of IGHV-34-positive HCL-v, and 5/7 of IGHV-34-positive HCL-c cases [<xref rid="B3" ref-type="bibr">3</xref>]. <italic>MAP2K1</italic> encodes mitogen-activated protein kinase kinase 1, which is a component of the MAP kinase signal transduction pathway. Somatic mutations were detected in HCL-v- and IGHV-34-positive HCL clusters in exons 2 and 3, which encode the N-terminal autoregulatory domain [<xref rid="B3" ref-type="bibr">3</xref>]. We detected negative results in all cases, which may be attributed to the small sample size and the low incidence of <italic>MAP2K1</italic> mutation.</p>
    <p>In conclusion, we analyzed <italic>BRAF</italic> V600E and <italic>MAP2K1</italic> mutations in a small series of HCL-c, HCL-v, and SMZL cases. The <italic>BRAF</italic> V600E mutation was detected in all cases of HCL-c, but in none of the HCL-v or SMZL cases. This observation is consistent with that of a previous study, confirming the diagnostic utility of <italic>BRAF</italic> testing in HCL. Considering the rarity of HCL cases, further studies are needed for drawing conclusive observations from a sufficiently large sample size.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>No potential conflicts of interest relevant to this article were reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tiacci</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Trifonov</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Schiavoni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kern</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Martelli</surname>
              <given-names>MP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>BRAF mutations in hairy-cell leukemia</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <fpage>2305</fpage>
          <lpage>2315</lpage>
          <pub-id pub-id-type="pmid">21663470</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Arons</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Navarro</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Calvo</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Stetler-Stevenson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Raffeld</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation</article-title>
          <source>Blood</source>
          <year>2012</year>
          <volume>119</volume>
          <fpage>3330</fpage>
          <lpage>3332</lpage>
          <pub-id pub-id-type="pmid">22210875</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waterfall</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Arons</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Pineda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Killian</surname>
              <given-names>JK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias</article-title>
          <source>Nat Genet</source>
          <year>2014</year>
          <volume>46</volume>
          <fpage>8</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">24241536</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Foucar</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Falini</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Catovsky</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <chapter-title>Hairy cell leukaemia</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Swerdlow</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <etal/>
          </person-group>
          <source>WHO classification of tumours of haematopoietic and lymphoid tissues</source>
          <edition>4th ed</edition>
          <publisher-loc>Lyon, France</publisher-loc>
          <publisher-name>International Agency for Research on Cancer</publisher-name>
          <year>2008</year>
          <fpage>188</fpage>
          <lpage>190</lpage>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kwak</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>WY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis</article-title>
          <source>Clin Chem Lab Med</source>
          <year>2013</year>
          <volume>51</volume>
          <fpage>1673</fpage>
          <lpage>1680</lpage>
          <pub-id pub-id-type="pmid">23585181</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Kown</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>MJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutant enrichment with 3'-modified oligonucleotides a practical PCR method for detecting trace mutant DNAs</article-title>
          <source>J Mol Diagn</source>
          <year>2011</year>
          <volume>13</volume>
          <fpage>657</fpage>
          <lpage>668</lpage>
          <pub-id pub-id-type="pmid">21979247</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davidsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lilljebjorn</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Panagopoulos</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fioretos</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias</article-title>
          <source>Leukemia</source>
          <year>2008</year>
          <volume>22</volume>
          <fpage>1619</fpage>
          <lpage>1621</lpage>
          <pub-id pub-id-type="pmid">18273045</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trifa</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Popp</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Cucuianu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Coada</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Urian</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Militaru</surname>
              <given-names>MS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms</article-title>
          <source>Leuk Lymphoma</source>
          <year>2012</year>
          <volume>53</volume>
          <fpage>2496</fpage>
          <lpage>2497</lpage>
          <pub-id pub-id-type="pmid">22339435</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Greaves</surname>
              <given-names>WO</given-names>
            </name>
            <name>
              <surname>Ravandi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bueso-Ramos</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay</article-title>
          <source>Am J Clin Pathol</source>
          <year>2012</year>
          <volume>138</volume>
          <fpage>153</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="pmid">22706871</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laurini</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Aoun</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Iqbal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Greiner</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders</article-title>
          <source>Am J Clin Pathol</source>
          <year>2012</year>
          <volume>138</volume>
          <fpage>877</fpage>
          <lpage>883</lpage>
          <pub-id pub-id-type="pmid">23161722</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <p>Basic characteristics and results of <italic>BRAF</italic> V600E and <italic>MAP2K1</italic> mutation analyses</p>
      </caption>
      <graphic xlink:href="alm-35-257-i001"/>
      <table-wrap-foot>
        <fn>
          <p><sup>*</sup>At initial diagnosis; Hb-WBC-PLT: 5.2 g/dL-1.01&#xD7;10<sup>9</sup>/L-36&#xD7;10<sup>9</sup>/L; <sup>&#x2020;</sup>At initial diagnosis; Hb-WBC-PLT: 9.7 g/dL-1.32&#xD7;10<sup>9</sup>/L-19&#xD7;10<sup>9</sup>/L.</p>
          <p>Abbreviations: WBC, white blood cell; PLT, platelet; F/U, follow-up; HCL, hairy cell leukemia; SMZL, splenic marginal zone lymphoma; NA, not available; R-CHOP, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab with cyclophosphamide, vincristine, and prednisone.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
